Lumira Ventures provides capital and operating expertise to life sciences companies developing innovative products that solve significant unmet needs of patients and healthcare providers. The firm has partners in Toronto, Montreal, Vancouver and Boston.

SpectraWAVE is a privately held medical device company founded to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). SpectraWAVE’s flagship HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab, and serves as a central hub for future enhancements that will continue to empower interventionalists in their treatment decision making and optimization.

Endogenex, a clinical stage company founded in partnership with Mayo Clinic, is focused on shifting the treatment paradigm for people living with Type 2 Diabetes. Current diabetes care focuses on the downstream consequences of this metabolic disease by targeting insulin resistance with medications and insulin replacement therapy. Endogenex’s goal is to reset the cellular signaling of the duodenum to help the body better manage blood sugar levels, via its endoscopic ReCET Procedure and the novel application of non-thermal pulsed electric field therapy to eliminate poorly signaling cells and induce regrowth of healthy cells that may restore proper metabolic signaling and potentially slow disease progression.

HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, brain, and others. HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Minnesota. The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy.

Cadence is developing a novel neuromodulation therapy for treating pediatric and adult patients with focal drug resistant epilepsy, originally developed at Mayo Clinic. The therapy utilizes chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy to reduce or eliminate seizures.

enGene Inc. is a clinical-stage biotechnology company developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical models, enGene's DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract and urinary tract.

PIC Therapeutics is a biotechnology company developing a new generation of cancer therapeutics based on the modulation of RNA translation.

GenEp, Inc. is a privately held pre-clinical stage biotechnology company, spun out of the University of Virginia, creating therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment resistant epilepsies.

Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company developing a novel therapy to restore smell and flavor function. The chronic loss of smell and flavor is a condition affecting at least 5% of the U.S. population with a similar incidence in Europe and Asia. The condition is now recognized as a widely prevalent long-term condition suffered by many patients who have recovered from COVID-19.

For over 60 seasons, Weston Drama Workshop has provided a summer theater residency program for performers in 5th grade through age 23. Over the season WDW inspires over 200 participants to offer over 20 fully staged productions over a 10-day period at the end of July.

Corvia Medical (formerly DC Devices) is developing the first trans-catheter device for diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF)

SEMDA and SEBIO have come together as a unified voice for the Southeast’s life-science industry. We connect biopharma, medical device, diagnostics, and digital heath industries with investors, potential partners, and the resources they need to progress.

Endotronix is a digital health medtech company developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. The company’s comprehensive solution includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure.

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac monitors to the industry. The company’s CAM Patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis.

Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company’s lead investigational drug is Staccato® alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures

Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company's CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach.

Prior to its acquisition by Stryker Corp., MAKO Surgical Corp. (Nasdaq: MAKO) was a medical device company pioneering the field of surgical robotics with a focus on knee and hip procedures.

Prior to its acquisition by Gilead Sciences, Pharmasset was a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, with a primary focus on oral therapeutics for the treatment of Hepatitis C.

Founding team member of this venture-backed provider of pharmaceutical licensing and business development enterprise solutions to improve drug development collaborations among pharmaceutical firms, biotechnology companies and academic medical research institutions. Acquired in 2002 by Wolters Kluwer N.V.